What is GLP-1? The complete guide

What GLP-1 is: the hormone, in plain English

Let us start with the question most people arrive with — what is GLP-1, and what does the term actually mean? The GLP-1 meaning is contained in its full name: glucagon-like peptide-1. It is a small hormone (a peptide) whose structure resembles another hormone called glucagon, and the “1” simply marks which fragment of a larger precursor protein it comes from.

GLP-1 is what scientists call an incretin hormone. That word sounds technical, but the idea is everyday: incretins are gut hormones that are released when you eat and that then tell the rest of the body to prepare for the food arriving. GLP-1 is secreted from specialised cells in the lining of your intestine, called L-cells, in response to nutrients passing through ^[8].

Once released, natural GLP-1 does several things at once ^[8]:

• It prompts the pancreas to release insulin — but only when blood glucose is high. This “glucose-dependent” action is important, because it means GLP-1 nudges insulin up mainly when it is actually needed.
• It suppresses glucagon, the hormone that raises blood sugar, helping keep glucose in check after a meal.
• It slows gastric emptying — the rate at which the stomach passes food into the intestine — so you feel full for longer.
• It acts on appetite and reward pathways in the brain, reducing how much you feel like eating.

Here is the catch that explains everything about the medicines that followed. Natural GLP-1 barely lasts in the bloodstream: its half-life is only about one to two minutes, because an enzyme called DPP-4 cleaves and inactivates it almost immediately ^[8]. You cannot simply inject the natural hormone and expect a lasting effect — it would be gone before it did much. That single problem is the reason an entire drug class exists.

How do GLP-1 medicines work?

A GLP-1 agonist(you will also see it written GLP1 agonist, or more precisely GLP-1 receptor agonist) is a laboratory-designed molecule that binds to and switches on the same receptor the natural glucagon-like peptide-1 hormone uses. In pharmacology, an “agonist” is anything that activates a receptor — so a GLP-1 agonist mimics the hormone's message.

The clever part is durability. These drugs are engineered to resist DPP-4, the enzyme that destroys natural GLP-1 within minutes ^[8]. Because they are not broken down quickly, most modern GLP-1 receptor agonists last for days rather than minutes, which is why several are given as a once-weekly injection under a skin fold using a pen device.

Once active, a GLP-1 receptor agonist reproduces the natural hormone's effects: glucose-dependent insulin release, glucagon suppression, slower gastric emptying, and reduced appetite signalling in the brain ^[8]. In practical terms, people in trials tended to feel fuller sooner and for longer. This is mechanism, not a marketing claim — how any of it plays out for an individual is something only a treating doctor can assess.

One important nuance: not every medicine grouped with “GLP-1 drugs” is a pure GLP-1 agonist. Tirzepatide, for example, is a dual GIP/GLP-1 receptor agonist— it activates two gut-hormone receptors, GIP as well as GLP-1 ^{[2] [11]}. It is discussed alongside GLP-1 medicines because of the shared GLP-1 action, but it is technically a different class. We flag this because the distinction matters when you read trial results and product labels. For a deeper look at individual molecules, see our guides to Mounjaro (tirzepatide) and semaglutide.

Which GLP-1 medicines are available in India?

Several GLP-1-based medicines exist internationally, and two flagship obesity injectables are now licensed and available in India according to business and trade press. The table below summarises the molecules, their common brand names, how they are given, and their regulatory status — this is factual regulatory information only, not a recommendation, and it excludes any pricing. Prescription medicines are never sold directly, and none of this should be read as advice to buy or use anything.

Brand names above are given only to help you orient yourself; the exact brand, indication and availability of each molecule can differ, and CDSCO approval status can change over time. What does not change is that all of these are prescription-only medicines. Whether any of them is suitable for a given person is a clinical decision, made by a registered medical practitioner after a consultation — never by a website, an advertisement, or the person themselves.

What the clinical trials show

The reason GLP-1 medicines are discussed so widely is the size of the randomised-controlled-trial evidence base. Below are the headline, attributed findings from the primary trials in our reference list. These are averages from studied populations under trial conditions — they describe what researchers observed, not what any individual should expect.

What are the side effects of GLP-1 medicines?

The most common side effects of GLP-1 medicines are gastrointestinal, which follows directly from how they work — slowing the stomach and dialling down appetite. On the US FDA label for semaglutide (Wegovy), the most common adverse reactions are nausea (44%), diarrhoea (30%), vomiting (24%), constipation (24%) and abdominal pain (20%) ^[10]. In the STEP 1 trial, nausea and diarrhoea were the most common events and were typically transient and mild to moderate ^[1].

Those effects can still lead some people to stop treatment. In STEP 1, discontinuation due to gastrointestinal events was 4.5% on semaglutide versus 0.8% on placebo ^[1]. In the much larger and longer SELECT trial, discontinuation for adverse events overall was 16.6% versus 8.2% for placebo ^[5]. In SURMOUNT-1, adverse-event-related discontinuation with tirzepatide ranged from 4.3% to 7.1% across doses versus 2.6% for placebo ^[2].

There are also serious safety considerations. The US FDA semaglutide label carries a boxed warning— the strongest type of warning — about thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), based on findings in animals ^[10]. The label states these medicines are contraindicated in people with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) ^[10].

This is the heart of why GLP-1 receptor agonists are prescription-only and require ongoing medical supervision. A doctor needs to review your history, check for contraindications, titrate the dose slowly to limit side effects, and monitor you over time. None of that can be replaced by an online purchase or a friend's experience. If you are curious about how injectable therapies are used inside a supervised program, our guide to weight loss injections in India explains the clinical framing in more detail.

Who might be evaluated for GLP-1 therapy

It is worth being precise here: no article can tell you whether a GLP-1 medicine is right for you, and MensMD does not decide that. What we can share is the regulatory framing that describes the populations these medicines were approved and studied for — the starting point a doctor uses, not a self-qualification checklist.

The US FDA label indicates semaglutide (Wegovy) for chronic weight management in eligible adults and adolescents aged 12 and older, and for cardiovascular risk reduction in adults with established heart disease and obesity or overweight ^{[10] [9]}. In India, trade press reports that Mounjaro (tirzepatide) is indicated for type 2 diabetes and for chronic weight management in adults with a BMI of at least 30, or at least 27 with a weight-related comorbidity ^[11].

Those thresholds are context for a conversation, not a verdict. A registered medical practitioner weighs your full picture — your BMI and body-fat distribution, blood sugar and other lab results, existing conditions, other medicines, family history, and the contraindications on the label — before deciding whether treatment is appropriate at all, and if so, which one. If in-person examination or further testing is needed first, that judgment stands. The appropriate next step is an assessment and a consultation, not a purchase.

GLP-1 and Indian patients: burden, cost and access

India carries a large metabolic-disease burden, which is why interest in this class is high here. The national ICMR-INDIAB study (n=113,043 adults across 31 states and union territories) estimated a weighted prevalence of diabetes at 11.4%, prediabetes at 15.3%, generalised obesity at 28.6%, abdominal obesity at 39.5%, hypertension at 35.5% and dyslipidaemia at 81.2% ^[7]. Globally, the WHO estimated that in 2022 about 2.5 billion adults (43%) were overweight and 890 million (16%) were living with obesity, and it characterises obesity as a chronic, relapsing disease and a risk factor for type 2 diabetes and cardiovascular disease ^[13].

On availability, India's two flagship licensed obesity injectables are, per trade press, Mounjaro (tirzepatide, the dual GIP/GLP-1 agonist, launched in 2025) and Wegovy (semaglutide, a pure GLP-1 receptor agonist, launched in June 2025) ^{[11] [12]}. These launches are recent, and the landscape is still evolving.

Access and cost are real considerations. These are premium, largely out-of-pocket therapies in India, and the trial evidence describes benefits that accrue while treatment continues — so they represent an ongoing commitment rather than a one-off. We do not publish prices for prescription medicines, and the practical realities of affordability, supply and long-term suitability are exactly the kind of thing to discuss with a doctor. If you want to understand how supervised, doctor-led care is structured — assessment, clinical review, and follow-up — you can explore the MensMD weight loss program, where any treatment decision always rests with a registered medical practitioner.

Frequently asked questions